The Role of Endothelin 1 as a Marker of Renal Impairment in Sickle Cell Disease - Trial NCT06158945
Access comprehensive clinical trial information for NCT06158945 through Pure Global AI's free database. This phase not specified trial is sponsored by Sohag University and is currently Recruiting. The study focuses on Sickle Cell Disease. Target enrollment is 30 participants.
This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.
Study Focus
Sponsor & Location
Sohag University
Timeline & Enrollment
N/A
Oct 24, 2023
Oct 23, 2024
Primary Outcome
renal affection in sickle cell patients
Summary
Sickle cell disease (SCD) refers to a group of hemoglobinopathies that include mutations in
 the gene encoding the beta subunit of hemoglobin. Within the umbrella of SCD, many subgroups
 exist, namely sickle cell anemia (SCA), hemoglobin SC disease (HbSC), and hemoglobin
 sickle-beta-thalassemia (beta-thalassemia positive or beta-thalassemia negative). Several
 other minor variants within the group of SCDs also, albeit not as common as the varieties
 mentioned above. It is essential to mention the sickle cell trait (HbAS), which carries a
 heterozygous mutation and seldom presents clinical signs or symptoms. Sickle cell anemia is
 the most common form of SCD
ICD-10 Classifications
Data Source
ClinicalTrials.gov
NCT06158945
Non-Device Trial